Supernus Pharmaceuticals (NASDAQ:SUPN) CEO Jack Khattar Sells 55,578 Shares

Key Points

• CEO Jack Khattar of Supernus Pharmaceuticals sold 55,578 shares at an average price of $46.01, resulting in a total transaction of approximately $2.56 million, and a ownership decrease of 4.77%.
• The stock experienced a minor decline, trading at $45.82 with a market capitalization of $2.57 billion and a 12-month high of $46.79.
• Analyst ratings for Supernus Pharmaceuticals vary, with a mix of "Buy," "Hold," and "Overweight" ratings, while the average price target stands at $43.00.

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) CEO Jack Khattar sold 55,578 shares of the company's stock in a transaction dated Friday, September 5th. The shares were sold at an average price of $46.01, for a total transaction of $2,557,143.78. Following the sale, the chief executive officer owned 1,110,231 shares of the company's stock, valued at $51,081,728.31. This trade represents a 4.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN traded down $0.18 during mid-day trading on Monday, hitting $45.82. The company had a trading volume of 594,918 shares, compared to its average volume of 639,735. The business's 50-day simple moving average is $38.01 and its 200-day simple moving average is $34.15. Supernus Pharmaceuticals, Inc. has a 12 month low of $29.16 and a 12 month high of $46.79. The firm has a market cap of $2.57 billion, a P/E ratio of 39.84 and a beta of 0.79.

Institutional Investors Weigh In On Supernus Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raiffeisen Bank International AG bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $25,000. Financial Management Professionals Inc. bought a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $30,000. Versant Capital Management Inc boosted its holdings in Supernus Pharmaceuticals by 6,931.3% in the 1st quarter. Versant Capital Management Inc now owns 1,125 shares of the specialty pharmaceutical company's stock valued at $37,000 after purchasing an additional 1,109 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in Supernus Pharmaceuticals in the 1st quarter valued at about $41,000. Finally, GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals in the 4th quarter valued at about $42,000.

Analysts Set New Price Targets

SUPN has been the subject of several recent research reports. Wall Street Zen raised shares of Supernus Pharmaceuticals from a "hold" rating to a "buy" rating in a research report on Saturday, August 2nd. Cantor Fitzgerald increased their price target on shares of Supernus Pharmaceuticals from $42.00 to $46.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. Zacks Research raised shares of Supernus Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 19th. Finally, Piper Sandler increased their price target on shares of Supernus Pharmaceuticals from $36.00 to $40.00 and gave the stock a "neutral" rating in a research report on Friday, August 29th. Two investment analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $43.00.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.